Axogen Inc (AXGN) - Total Assets
Based on the latest financial reports, Axogen Inc (AXGN) holds total assets worth $289.49 Million USD as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore AXGN operating cash to total liabilities to assess how comfortably operating cash covers total debt obligations.
Axogen Inc - Total Assets Trend (1986–2025)
This chart illustrates how Axogen Inc's total assets have evolved over time, based on quarterly financial data. See Axogen Inc (AXGN) net assets for net asset value and shareholders' equity analysis.
Axogen Inc - Asset Composition Analysis
Current Asset Composition (December 2025)
Axogen Inc's total assets of $289.49 Million consist of 54.3% current assets and 45.7% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 16.0% |
| Accounts Receivable | $26.17 Million | 11.8% |
| Inventory | $42.37 Million | 19.1% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $6.75 Million | 3.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (1986–2025)
This chart illustrates how Axogen Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see AXGN stock market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Axogen Inc's current assets represent 54.3% of total assets in 2025, an increase from 35.8% in 1986.
- Cash Position: Cash and equivalents constituted 16.0% of total assets in 2025, up from 14.9% in 1986.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 3.0% of total assets, an increase from 1.0% in 1986.
- Asset Diversification: The largest asset category is inventory at 19.1% of total assets.
Axogen Inc Competitors by Total Assets
Key competitors of Axogen Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Bio-Rad Laboratories Inc
NYSE:BIO
|
USA | $9.79 Billion |
|
Double Medical Technology Inc
SHE:002901
|
China | CN¥5.03 Billion |
|
Tellgen Corp
SHE:300642
|
China | CN¥2.01 Billion |
|
Affluent Medical SAS
PA:AFME
|
France | €59.84 Million |
|
Cochlear Ltd
AU:COH
|
Australia | AU$2.83 Billion |
|
4DMEDICAL Ltd
AU:4DX
|
Australia | AU$139.55 Million |
|
Anteris Technologies Global Corp
AU:AVR
|
Australia | AU$19.07 Million |
|
Imricor Medical Systems Inc
AU:IMR
|
Australia | AU$45.79 Million |
Axogen Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 7.10 | 4.28 | 6.56 |
| Quick Ratio | 5.33 | 2.65 | 5.94 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $158.69 Million | $71.33 Million | $120.17 Million |
Axogen Inc - Advanced Valuation Insights
This section examines the relationship between Axogen Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 9.20 |
| Latest Market Cap to Assets Ratio | 10.13 |
| Asset Growth Rate (YoY) | 8.8% |
| Total Assets | $221.69 Million |
| Market Capitalization | $2.24 Billion USD |
Valuation Analysis
Premium Asset Valuation: The market values Axogen Inc's assets at a significant premium (10.13x), suggesting investors see substantial growth potential or unique competitive advantages.
Positive Asset Growth: Axogen Inc's assets grew by 8.8% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Axogen Inc (1986–2025)
The table below shows the annual total assets of Axogen Inc from 1986 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $221.69 Million | +8.82% |
| 2024-12-31 | $203.73 Million | +3.51% |
| 2023-12-31 | $196.83 Million | +0.74% |
| 2022-12-31 | $195.39 Million | -6.07% |
| 2021-12-31 | $208.02 Million | +3.30% |
| 2020-12-31 | $201.38 Million | +30.22% |
| 2019-12-31 | $154.64 Million | -3.45% |
| 2018-12-31 | $160.17 Million | +172.06% |
| 2017-12-31 | $58.87 Million | +26.99% |
| 2016-12-31 | $46.36 Million | +23.48% |
| 2015-12-31 | $37.55 Million | +128.93% |
| 2014-12-31 | $16.40 Million | -40.76% |
| 2013-12-31 | $27.68 Million | +36.84% |
| 2012-12-31 | $20.23 Million | +61.91% |
| 2011-12-31 | $12.50 Million | +23.18% |
| 2010-12-31 | $10.14 Million | -39.65% |
| 2009-12-31 | $16.81 Million | +3106.23% |
| 2008-12-31 | $524.24K | -52.34% |
| 2007-12-31 | $1.10 Million | -27.38% |
| 2006-12-31 | $1.51 Million | -17.00% |
| 2005-12-31 | $1.82 Million | -34.90% |
| 2004-12-31 | $2.80 Million | +4.18% |
| 2003-12-31 | $2.69 Million | -35.17% |
| 2002-12-31 | $4.15 Million | -34.64% |
| 2001-12-31 | $6.35 Million | -25.07% |
| 2000-12-31 | $8.47 Million | -3.70% |
| 1999-12-31 | $8.80 Million | -16.98% |
| 1998-12-31 | $10.60 Million | -10.17% |
| 1997-12-31 | $11.80 Million | -4.07% |
| 1996-12-31 | $12.30 Million | -3.15% |
| 1995-12-31 | $12.70 Million | 0.00% |
| 1994-12-31 | $12.70 Million | 0.00% |
| 1993-12-31 | $12.70 Million | +15.45% |
| 1992-12-31 | $11.00 Million | +5.77% |
| 1991-12-31 | $10.40 Million | +9.47% |
| 1990-12-31 | $9.50 Million | +13.10% |
| 1989-12-31 | $8.40 Million | -85.57% |
| 1988-12-31 | $58.20 Million | +743.48% |
| 1987-12-31 | $6.90 Million | +2.99% |
| 1986-12-31 | $6.70 Million | -- |
About Axogen Inc
Axogen, Inc., together with its subsidiaries, engages in the development and commercialization of the technologies used for peripheral nerve regeneration and repair worldwide. The company offers Avance Nerve Graft, a processed nerve allograft intended for the surgical repair of peripheral nerve discontinuities; Axoguard Nerve Connector, a coaptation aid used to align and connect severed periphera… Read more